Feb. 24, 2020 – As the country prepares for a national election on Nov. 3, the Coalition for Healthcare Communication is endorsing the nonpartisan “Time to Vote” initiative developed by a coalition of U.S. companies that seeks to ensure that all employees have a work schedule that allows them to vote in elections. “Politics is […]
Read more
Feb. 11, 2020 – John Kamp, who served for 16 years as the executive director of the Coalition for Healthcare Communication, last week was inducted into the Medical Advertising Hall of Fame (MAHF) and given the MAHF’s 2020 Service to Industry Award. “John is a wise, shrewd, and articulate defender of the First Amendment right […]
Read more
Jan. 13, 2020 — Jay Carter, RPh, has been elected Chair of the Executive Committee of the Coalition for Healthcare Communication for 2020-2021. He succeeds Karsten Risch, M.D., Ph.D., M.P.H., who served in 2018-2019. “We are in an election year where our industry will be continuously scrutinized and criticized,” said Carter. “Business as usual. I’m […]
Read more
Sept. 20, 2019 – Although the House proposal unveiled by House Speaker Nancy Pelosi (D-Calif.) to combat high drug prices would cap Medicare drug prices based on the average price in six developed countries, require that the federal government and drug companies negotiate prices for up to 250 of the most expensive prescription drugs, mandate […]
Read more
May 23, 2019 – Concern over drug pricing remains a healthcare policy issue that enjoys bipartisan support and will remain on the table for the Trump administration and Congress as campaigns for the 2020 election ramp up, according to Kate Rawson, senior editor at Prevision Policy. Speaking at a session of the Coalition for Healthcare […]
Read more March 25, 2019 – Several moves that could change the way prescription drug marketing and communications are conducted are being made in Washington, with the House Ways and Means Committee about to begin markup on a tax measure that could include eliminating the deductibility of drug marketing costs, and the Office of Management and Budget […]
Read more
Feb. 25, 2019 – Even as the Centers for Medicare & Medicaid Services considers comments received on a federal proposal to mandate the inclusion of the wholesale acquisition cost (WAC) of prescription drugs in consumer television ads, the state of Oregon is weighing whether or not to require a disclosure regarding the wholesale cost that […]
Read more
Nov. 19, 2018 – In a featured “Perspective” article in The New England Journal of Medicine (NEJM) this week, Stacie B. Dusetzina, Ph.D., and Michelle M. Mello, J.D., Ph.D., state that although providing cost information about prescription drugs is valuable, mandating that companies use the wholesale acquisition cost (WAC) in direct-to-consumer (DTC) ads “raises substantial […]
Read more
Oct. 19, 2018 — The FDA’s Office of Prescription Drug Promotion (OPDP) issued two enforcement actions in less than a week that focused on alleged safety and risk information infractions for products with Boxed Warnings; both matters were brought to the agency’s attention through OPDP’s Bad Ad program. “These letters are significant not because they […]
Read more
Sept. 27, 2018 – Although it was the Obama administration’s position that reprints and textbooks received by physicians were transfers of value that were fully reportable under the Sunshine Act Open Payments regulation, the Trump administration and Congress are taking another look at the matter, according to John Kamp, Washington Counsel, Coalition for Healthcare Communication. […]
Read more